Seizure recurrence chance after antiepileptic drug withdrawal and its correlation with drug level and other laboratory parameters

Not Applicable

• Conditions: Health Condition 1: null- Persons with epilepsy undergoing antiepileptic drug tapering after more than 2 years of seizure free period

• Registration Number: CTRI/2017/04/008392
• Lead Sponsor: All India Institute of Medical Sciences New Delhi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 330

Inclusion Criteria

1. Clinically diagnosed persons with epilepsy (PWE)

2. Either male or female, age more than 18 years

3. On monotherapy of AEDs (valproic acid, carbamazepine, phenytoin and levetiracetam)

4. Two years seizure freedom or longer

5. PWE going to start AED tapering

6. Patient ready to give informed consent

Exclusion Criteria

1. Juvenile myoclonic epilepsy

2. Pregnant or seeking pregnancy

3. Associated neurological diseases other than epilepsy

4. Patient on drugs known to alter seizure threshold (e.g. INH, theophylline, metronidazole etc.)

5. Patient with significant hepatic and renal impairment that may require dose alteration

6. Patient on anti tubercular drugs or any other drugs known to cause interaction with AEDs (e.g. isoniazid, fluoxetine, fluvoxamine, clarithromycin, erythromycin, fluconazole etc.)

7. Patient on food or dietary supplements like grape fruit juice and ginkgo biloba which are known to cause interaction with AEDs

8. Any associated psychiatric disorder

9. Any chronic inflammatory disorder (e.g. Autoimmune disorder like RA, IBD, bronchial asthma)

10. Patient refuses to give informed consent

Study & Design

• Study Type: Observational
• Study Design: Not specified